News | June 17, 2024
Devyser announces expanded commercial agreement with Thermo Fisher Scientific for post-transplant monitoring NGS products
Find out more
News (2)
Devyser wins all-time high tender for up to 75 MSEK
Devyser wins tender for oncology NGS solutions in Italy
Devyser wins tender for thalassemia in Italy
Devyser Diagnostics AB publishes quarterly report for the period January to March 2024
Devyser receives IVDR approval for post-transplant monitoring software
Devyser partners with Hamilton to automate laboratory NGS workflows
Devyser receives MDSAP certification for Brazil
Devyser publishes annual report for 2023
Devyser´s annual report 2023 has today been published on the company´s website. The report is...
Devyser achieves breakthrough in the US with cystic fibrosis NGS test
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is...
Devyser announces study publication demonstrating dd-cfDNA detection in dual donor kidney transplant patients
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...
Devyser Diagnostics AB publishes year-end report for January to December 2023
“Devyser is able to report strong sales growth and record high gross margins for the fourth...